Publications by authors named "Y Nagane"
International consensus guidance and Japanese clinical guidelines for myasthenia gravis (MG) recommend achieving minimal manifestations or better status (MM-or-better) as the severity component of the treatment goal. However, the subjective nature of determining MM can result in ambiguity regarding this category in clinical practice and clinical trials. This study analyzed severity metrics in a large number of MG patients to propose criteria for MM-or-better.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the safety of statins in patients with myasthenia gravis (MG), particularly focusing on muscle-related symptoms and potential worsening of myasthenic symptoms.
- Among 1710 MG patients reviewed, only 2% experienced statin intolerance, and 1.5% showed myasthenic worsening, with common issues like ptosis.
- The findings suggest that while statin-associated myasthenic worsening is rare and generally mild, symptoms improve quickly after stopping the medication, indicating statins can be safely used in MG patients with some caution.
Article Synopsis
- A study analyzed the incidence of taste disorders and alopecia in 1,710 myasthenia gravis (MG) patients, revealing 6.1% had taste issues and 8.2% experienced hair loss.
- Taste disorders were more common in women and those with severe or thymoma-associated MG, often appearing after MG onset and responding to treatments.
- Alopecia was linked to patients with bulbar palsy and thymoma, frequently occurring before MG onset and sometimes responding to treatment, highlighting the need for clinicians to recognize these non-motor symptoms in severe MG cases.
Article Synopsis
- Eculizumab and ravulizumab are effective treatments for patients with anti-acetylcholine receptor-positive generalized myasthenia gravis, showing good results in both clinical trials and real-world experiences.
- In a study of 1,106 patients, 36 received eculizumab, leading to significant clinical improvement for the majority, with 70% showing a positive response.
- Patients switching to ravulizumab reported continued effectiveness and a preference for ravulizumab over eculizumab, indicating it may be a favorable option for ongoing treatment.